Respiratory Inhaler Device Market Size & Share, by Product (Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers); Technology (Manually Operated Inhalers Devices, Digitally Operated Inhalers Devices); Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Disease) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 202
  • Published Date: Sep 04, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Respiratory Inhaler Device Market size was valued at USD 37.07 billion in 2023 and is likely to reach USD 68.19 billion by 2036, expanding at around 4.8% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of respiratory inhaler device is estimated at USD 38.49 billion.

The growth of the market can be attributed to increasing cases of chronic obstructive pulmonary diseases. Furthermore, the data published by the World Health Organization states that asthma affected 262 million people in 2019 and caused 455,000 deaths worldwide. The inhaled medication can control asthma symptoms, which is the reason global market is projected to grow significantly during the forecast period. Additionally, the prevalence of chronic obstructive pulmonary diseases is directly related to tobacco smoking. The data released by the Institutes for Health Metrics and Evaluation states that the number of smokers is rising worldwide and in 2019, smoking caused 8 million deaths. On the back of an escalating number of people involved in smoking the market is estimated to grow significantly during the forecast period. The inhalers are effective in providing relief to common cold patients. On account of the efficacy in providing relief to common cold patients, the respiratory inhaler device market is projected to grow during the forecast period.


Get more information on this report: Request Free Sample PDF

Respiratory Inhaler Device Sector: Growth Drivers and Challenges

Growth Drivers  

  • Rising Air Pollution

  • Growing Cases of Asthma
  • Increasing Patients with Chronic Obstructive Pulmonary Disease 

Challenges 

  • Associated Side-Effects

Respiratory Inhaler Device Market: Key Insights

Base Year

2023

Forecast Year

2024–2036

CAGR

4.8%

Base Year Market Size (2023)

USD 37.07 billion

Forecast Year Market Size (2036)

USD 68.19 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Respiratory Inhaler Device Segmentation

The respiratory inhaler device market is segmented by disease indication into asthma, chronic obstructive pulmonary disease, pulmonary disease, and others. Out of which, the asthma sub-segment is anticipated to hold the largest share in the global market on account of the aggressively increasing number of patients with asthma. Respiratory inhalers are highly effective in controlling asthma symptoms.

Our in-depth analysis of the global respiratory inhaler device market includes the following segments:

           Product

  • Dry Powder Inhalers
  • Metered Dose Inhalers
  • Nebulizers

             Technology

  • Manually Operated Inhalers Devices
  • Digitally Operated Inhalers Devices

 

 

           Disease Indication

  • Asthma
  • Chronic Obstructive Pulmonary Disease
  • Pulmonary Disease
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Respiratory Inhaler Device Industry - Regional Synopsis

Regionally, the global respiratory inhaler device market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America is estimated to account for largest revenue share by 2036, on the back of presence of a highly established healthcare infrastructure. Furthermore, the Centers for Disease Control and Prevention states that chronic obstructive pulmonary diseases affect more than 15 million Americans. Owing to this, the global market is projected to witness remarkable growth during the forecast period. Apart from this, a report published by the National Center for Biotechnology Information states that 5% of adults suffer from acute bronchitis every year. A person suffering from bronchitis might receive a nebulizer breathing treatment which calms the inflation in the mucous membrane and allow the body to start to heal.

The Asia Pacific region is also estimated to witness significant growth during the forecast period on the back large number of people suffering from respiratory diseases.  Also, the data released by the WHO, countries such as, Bangladesh, India, and Pakistan are among the most polluted countries in the world, all exceeding WHO guidelines by 10 times. The increasing air pollution in the region is leading to severe respiratory diseases among the population, which is the reason the global respiratory inhaler device market is projected to witness significant growth during the forecast period.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the Respiratory Inhaler Device Landscape

    • Teva Pharmaceuticals Industries Ltd.
      • Company Overview 
      • Business Strategy 
      • Key Product Offerings 
      • Financial Performance 
      • Key Performance Indicators 
      • Risk Analysis 
      • Recent Development 
      • Regional Presence 
      • SWOT Analysis 
    • Beximco Pharmaceuticals Ltd.
    • Omron Healthcare Europe B.V
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.,
    • GlaxoSmithKline plc.
    • Cipla Inc.
    • Koninklijke Philips N.V.,
    • PARI GmbH
    • AstraZeneca plc

In the News

  • December 12, 2021: PetMedix, a UK based research, and development stage biopharmaceutical company joins hand with Boehringer Ingelheim to develop animal antibody therapeutics.

Author Credits:  Radhika Pawar


  • Report ID: 202
  • Published Date: Sep 04, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of respiratory inhaler device is estimated at USD 38.49 billion.

Respiratory Inhaler Device Market size was valued at USD 37.07 billion in 2023 and is likely to reach USD 68.19 billion by 2036, expanding at around 4.8% CAGR during the forecast period i.e., between 2024-2036. The rising cases of chronic obstructive pulmonary diseases will impel the market growth.

North America is estimated to account for largest revenue share by 2036, on the back of presence of a highly established healthcare infrastructure.

The major players in the market are Merck & Co., Inc., GlaxoSmithKline plc., Cipla Inc., and Koninklijke Philips N.V.
Respiratory Inhaler Device Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample